Literature DB >> 8872175

Human leukocyte antigen-DRB1*1502 (DR2Dw12) transgene reduces incidence and severity of arthritis in mice.

M A Gonzalez-Gay1, E Zanelli, S D Khare, C J Krco, P Zhou, H Inoko, M M Griffiths, H S Luthra, C S David.   

Abstract

A strong correlation exists between susceptibility to RA in humans and some DRB1 alleles of the MHC region, such as DRB1*0401 and DRB1*0101. Meanwhile, incidences of other DR specificities, such as DR2, DR5, or DR7 have often been found reduced among RA patients. Like RA, susceptibility to mouse CIA is influenced by the MHC class II loci. To analyze the effect of a DRB1 molecule associated with low incidence of RA on mouse CIA, a human DRB1*1502 (DR2Dw12) transgene was introduced into CIA-susceptible B10.RQB3 (H2Aq) mice. Transgene-positive DRB1*1502 mice showed a significant reduction in the incidence and severity of arthritis. Moreover, the clinical reduction of arthritis correlated with the T-cell proliferative response of B10.RQB3-DRB1*1502 mice against a self-derived DRB1 peptide from the third hypervariable region. Our results suggest that the DRB1*1502-mediated protection against CIA can be explained by the DRB1 molecule acting as a source of self-antigenic peptide which interferes with the T-cell response against immunodominant regions(s) of the arthritogenic type II collagen molecule. By analogy, a similar mechanism might play a critical role in influencing the class II-associated predisposition to RA.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8872175     DOI: 10.1016/0198-8859(96)00123-1

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  14 in total

1.  Recombinant T cell receptor ligand treatment improves neurological outcome in the presence of tissue plasminogen activator in experimental ischemic stroke.

Authors:  Wenbin Zhu; Nicole L Libal; Amanda Casper; Sheetal Bodhankar; Halina Offner; Nabil J Alkayed
Journal:  Transl Stroke Res       Date:  2014-06-24       Impact factor: 6.829

2.  A novel HLA-DRα1-MOG-35-55 construct treats experimental stroke.

Authors:  Gil Benedek; Wenbin Zhu; Nicole Libal; Amanda Casper; Xiaolin Yu; Roberto Meza-Romero; Arthur A Vandenbark; Nabil J Alkayed; Halina Offner
Journal:  Metab Brain Dis       Date:  2014-03       Impact factor: 3.584

Review 3.  HLA transgenic mice as humanized mouse models of disease and immunity.

Authors:  V Taneja; C S David
Journal:  J Clin Invest       Date:  1998-03-01       Impact factor: 14.808

Review 4.  Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies.

Authors:  Frank R Brennan; Laura Dill Morton; Sebastian Spindeldreher; Andrea Kiessling; Roy Allenspach; Adam Hey; Patrick Y Muller; Werner Frings; Jennifer Sims
Journal:  MAbs       Date:  2010-05-23       Impact factor: 5.857

5.  Preclinical evaluation of recombinant T cell receptor ligand RTL1000 as a therapeutic agent in ischemic stroke.

Authors:  Wenbin Zhu; Amanda Casper; Nicole L Libal; Stephanie J Murphy; Sheetal Bodhankar; Halina Offner; Nabil J Alkayed
Journal:  Transl Stroke Res       Date:  2014-10-02       Impact factor: 6.829

6.  Recombinant T cell receptor ligands improve outcome after experimental cerebral ischemia.

Authors:  Kozaburo Akiyoshi; Suzan Dziennis; Julie Palmateer; Xuefang Ren; Arthur A Vandenbark; Halina Offner; Paco S Herson; Patricia D Hurn
Journal:  Transl Stroke Res       Date:  2011-09-01       Impact factor: 6.829

7.  Recombinant T-cell receptor ligand RTL1000 limits inflammation and decreases infarct size after experimental ischemic stroke in middle-aged mice.

Authors:  W Zhu; A L Dotson; N L Libal; A S Lapato; S Bodhankar; H Offner; N J Alkayed
Journal:  Neuroscience       Date:  2014-12-31       Impact factor: 3.590

8.  HLA-DQB1 polymorphism determines incidence, onset, and severity of collagen-induced arthritis in transgenic mice. Implications in human rheumatoid arthritis.

Authors:  D S Bradley; G H Nabozny; S Cheng; P Zhou; M M Griffiths; H S Luthra; C S David
Journal:  J Clin Invest       Date:  1997-11-01       Impact factor: 14.808

9.  Recombinant T cell receptor ligand treats experimental stroke.

Authors:  Sandhya Subramanian; Bing Zhang; Yasuharu Kosaka; Gregory G Burrows; Marjorie R Grafe; Arthur A Vandenbark; Patricia D Hurn; Halina Offner
Journal:  Stroke       Date:  2009-05-14       Impact factor: 7.914

10.  A vaccine encoding conserved promiscuous HIV CD4 epitopes induces broad T cell responses in mice transgenic to multiple common HLA class II molecules.

Authors:  Susan Pereira Ribeiro; Daniela Santoro Rosa; Simone Gonçalves Fonseca; Eliane Conti Mairena; Edilberto Postól; Sergio Costa Oliveira; Luiza Guilherme; Jorge Kalil; Edecio Cunha-Neto
Journal:  PLoS One       Date:  2010-06-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.